id,collection,Type de document,Type d'article,DOI,PMID,URL,Titre,Auteur(s),Titre de la revue,Nom court de la revue,Date de publication,ISSN,Mot(s)-clé(s),Discipline(s) HAL,Résumé en anglais,Langue,Audience,Vulgarisation,Collection
"c574cd31-e522-441e-8bf6-05bef0a9e1b3","20.500.12210/20","Article dans une revue scientifique","Article de synthèse/Review paper","10.1016/j.jormas.2021.05.005","34000438","http://hdl.handle.net/20.500.12210/78844","Dental discoloration following Le Fort 1 osteotomy, a systematic review","Piot, Nolwenn||Schlund, Matthias||Ferri, Joel","Journal of Stomatology, Oral and Maxillofacial Surgery","J Stomatol Oral Maxillofac Surg","2021-05-24","2468-7855","Pulpal blood flow||Dental discoloration||Maxillary osteotomy||Orthognathic surgery||Le Fort 1 osteotomy","Sciences du Vivant [q-bio]","Introduction: This study was conducted to review current knowledge concerning factor and how to proceed with dental discoloration after Le Fort 1 osteotomy (LF1O). Material & Methods:  A systematic search of the literature was performed in PubMed/Medline and Cochrane library until December 1, 2020 using the following key words: “dental discoloration and osteotomy”, “dental discoloration and Le Fort”, “dental discoloration and orthognathic”, “dental discoloration and surgery”, “tooth discoloration and osteotomy”, “tooth discoloration and Le Fort”, “tooth discoloration and orthognathic”, “tooth discoloration and surgery”. Results: 705 studies were located by initial screening; 232 were duplicate, 468 did not meet the eligibility criteria, leaving 5 studies. The post-operative follow-up period of the included studies ranged from 6 months to 2 years. Conclusion: The present revue found dental discoloration can occur after LF1O in 3.56% of the cases. The follow-up before treatment should be around one years. If the discoloration persisted and pulpal sensibility test is negative, the tooth should be treated. If the pulpal sensibility test is positive, follow-up should be carry on.","Anglais","Internationale","Non","Advanced Drug Delivery Systems (ADDS) - U1008"
